Outcomes and risk factors for mortality among patients treated with carbapenems for klebsiella spp. bacteremia

PLoS ONE

Volumn 10, Issue 11, 2015, Pages

  Biehle, Lauren R ^a,b,e   Cottreau, Jessica M ^a,b,f   Thompson, David J ^c   Filipek, Rachel L ^c   O'Donnell, J Nicholas ^c,d   Lasco, Todd M ^b   Mahoney, Monica V ^d   Hirsch, Elizabeth B ^c,d  

^a UNIVERSITY OF HOUSTON   (United States)

^b CHI ST LUKE S HEALTH BAYLOR ST LUKE S MEDICAL CENTER   (United States)

^c NORTHEASTERN UNIVERSITY   (United States)

^d BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^e UNIVERSITY OF WYOMING   (United States)

^f ROSALIND FRANKLIN UNIVERSITY OF MEDICINE AND SCIENCE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOGLYCOSIDE ANTIBIOTIC AGENT; CARBAPENEM DERIVATIVE; CEPHALOSPORIN; DORIPENEM; ERTAPENEM; IMIPENEM; PIPERACILLIN PLUS TAZOBACTAM; QUINOLINE DERIVED ANTIINFECTIVE AGENT;

ADULT; ARTICLE; BACTEREMIA; BACTERIUM IDENTIFICATION; CONTROLLED STUDY; DRUG EFFECT; DRUG RESPONSE; FEMALE; HUMAN; INFECTION RISK; KLEBSIELLA PNEUMONIAE; LENGTH OF STAY; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MINIMUM INHIBITORY CONCENTRATION; MORTALITY; NONHUMAN; OUTCOME ASSESSMENT; RISK ASSESSMENT; RISK FACTOR; SCORING SYSTEM; AGED; ANTIBIOTIC RESISTANCE; KLEBSIELLA INFECTIONS; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

AGED; BACTEREMIA; CARBAPENEMS; DRUG RESISTANCE, BACTERIAL; FEMALE; HUMANS; KLEBSIELLA INFECTIONS; LENGTH OF STAY; MALE; MIDDLE AGED; RISK FACTORS; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 84957072521     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0143845     Document Type: Article

References (17)

1. Michalopoulos A, Falagas ME, Karatza DC, Alexandropoulou P, Papadakis E, Gregorakos L, et al. Epidemiologic, clinical characteristics, and risk factors for adverse outcome in multiresistant gram-negative primary bacteremia of critically ill patients. Am J Infect Control 2011 39: 396-400. doi: 10.1016/j.ajic. 2010.06.017 PMID: 21035919
2. Luzzaro F, Ortisi G, Larosa M, Drago M, Brigante G, Gesu G Prevalence and epidemiology of microbial pathogens causing bloodstream infections: results of the OASIS multicenter study. Diagn Microbiol Infect Dis 2011 69: 363-369. doi: 10.1016/j.diagmicrobio.2010.10.016 PMID: 21396530
3. Kontopidou F, Giamarellou H, Katerelos P, Maragos A, Kioumis I, Trikka-Graphakos E, et al. Infections caused by carbapenem-resistant Klebsiella pneumoniae among patients in intensive care units in Greece: a multi-centre study on clinical outcome and therapeutic options. Clin Microbiol Infect 2014 20: O117-123. doi: 10.1111/1469-0691.12341 PMID: 23992130
4. Ben-David D, Kordevani R, Keller N, Tal I, Marzel A, Gal-Mor O, et al. Outcome of carbapenem resistant Klebsiella pneumoniae bloodstream infections. Clin Microbiol Infect 2012 18: 54-60.
5. Daikos GL, Tsaousi S, Tzouvelekis LS, Anyfantis I, Psichogiou M, Argyropoulou A, et al. Carbapenemase-producing Klebsiella pneumoniae bloodstream infections: lowering mortality by antibiotic combination schemes and the role of carbapenems. Antimicrob Agents Chemother 2014 58: 2322-2328. doi: 10.1128/AAC.02166-13 PMID: 24514083
6. Hirsch EB, Tam VH. Detection and treatment options for Klebsiella pneumoniae carbapenemases (KPCs): an emerging cause of multidrug-resistant infection. J Antimicrob Chemother 2010 65: 1119-1125. doi: 10.1093/jac/dkq108 PMID: 20378670
7. Qureshi ZA, Paterson DL, Potoski BA, Kilayko MC, Sandovsky G, Sordillo E, et al. Treatment outcome of bacteremia due to KPC-producing Klebsiella pneumoniae: superiority of combination antimicrobial regimens. Antimicrob Agents Chemother 2012 56: 2108-2113. doi: 10.1128/AAC.06268-11 PMID: 22252816
8. Tumbarello M, Viale P, Viscoli C, Trecarichi EM, Tumietto F, Marchese A, et al. Predictors of mortality in bloodstream infections caused by Klebsiella pneumoniae carbapenemase-producing K. pneumoniae: importance of combination therapy. Clin Infect Dis 2012 55: 943-950. doi: 10.1093/cid/cis588 PMID: 22752516
9. Clinical and Laboratory Standards Institute. 2012. Performance standards for antimicrobial susceptibility testing; twenty-second informational supplement. M100-S22. Wayne, PA.
10. Magiorakos AP, Srinivasan A, Carey RB, Carmeli Y, Falagas ME, Giske CG, et al. Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance. Clin Microbiol Infect Dis 2012 18: 268-281.
11. Nguyen M, Eschenauer GA, Bryan M, O'Neil K, Furuya EY, Della-Latta P, et al. Carbapenem-resistant Klebsiella pneumoniae bacteremia: factors correlated with clinical and microbiologic outcomes. Diagn Microbiol Infect Dis 2010 67: 180-184. doi: 10.1016/j.diagmicrobio.2010.02.001 PMID: 20356699
12. Zarkotou O, Pournaras S, Tselioti P, Dragoumanos V, Pitiriga V, Ranellou K, et al. Predictors of mortality in patients with bloodstream infections caused by KPC-producing Klebsiella pneumoniae and impact of appropriate antimicrobial treatment. Clin Microbiol Infect 2011.
13. Falagas ME, Tansarli GS, Karageorgopoulos DE, Vardakas KZ Deaths attributable to carbapenemresistant Enterobacteriaceae infections. Emerging Infect Dis 2014 20: 1170-1175. doi: 10.3201/ eid2007.121004 PMID: 24959688
14. Lee NY, Huang WH, Tsui KC, Hsueh PR, Ko WC Carbapenem therapy for bacteremia due to extended-spectrum beta-lactamase-producing Escherichia coli or Klebsiella pneumoniae. Diagn Microbiol Infect Dis 2011 70: 150-153. doi: 10.1016/j.diagmicrobio.2010.12.008 PMID: 21398070
15. Lee NY, Lee CC, Huang WH, Tsui KC, Hsueh PR, Ko WC Carbapenem therapy for bacteremia due to extended-spectrum-beta-lactamase-producing Escherichia coli or Klebsiella pneumoniae: implications of ertapenem susceptibility. Antimicrob Agents Chemother 2012 56: 2888-2893. doi: 10.1128/AAC. 06301-11 PMID: 22430969
16. Hirsch EB, Chang KT, Lasco TM, Caeiro JP, Tam VH Emergence of KPC-producing Klebsiella pneumoniae in Texas. Diagn Microbiol Infect Dis 2011 69: 234-235. doi: 10.1016/j.diagmicrobio.2010.09. 003 PMID: 21251574
17. Tam VH, Hirsch EB, Lasco TM, Gentry LO, Palmer HR Correlation of hospital carbapenem consumption and resistance trends in selected gram-negative bacteria. Ann Pharmacother 2012 46: 1120-1122. doi: 10.1345/aph.1R021 PMID: 22764323